NDAORALCAPSULEPriority Review
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
LENVIMA (lenvatinib) by Eisai is receptor tyrosine kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2015.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LENVIMA (lenvatinib) is an oral receptor tyrosine kinase inhibitor approved in 2015 for multiple cancer indications. It works by blocking multiple kinase pathways to inhibit tumor growth and angiogenesis. The drug is indicated across several solid tumor types where kinase-driven pathways are therapeutically relevant.
$0.779BPart D
PeakStable
12.4 years to LOEPeak lifecycle product with stable $779M annual spending and strong patient base indicates established commercial infrastructure with moderate team sizes focused on market maintenance rather than expansion.
Mechanism of Action
Receptor Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Started Mar 2026
87 enrolled
Cervical Cancer by FIGO Stage 2018Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Started Oct 2025
140 enrolled
Hepatocellular Carcinoma
Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
Started Oct 2025
120 enrolled
Cervical Cancer
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Started Aug 2025
65 enrolled
Biliary Tract CancerDisitamab VedotinLenvatinib+1 more
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Started Aug 2025
114 enrolled
Hepatocellular Carcinoma
Worked on LENVIMA at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.